Gleiss Lutz has advised Israeli venture capital investor Pitango on its investment in digital health startup Patient21. The Berlin-based startup raised a total of EUR 100 million from investors in Series C funding. The round was led by Pitango.
Patient21 buys dental and medical practices across Germany, digitises them and then operates them under the startup's brand name. The central element is a cloud-based digital platform that consolidates the entire patient journey – from booking appointments to diagnosis and therapy – and centralises patient information such as medical records. Patient21 has already acquired and integrated 53 medical practices with around 700 employees.
Founded in 1993, Pitango is Israel's largest venture capital investor, whose three dedicated investment funds Pitango First, Pitango Growth and Pitango HealthTech have over USD 3 billion under management and investments in over 250 companies.
The following team of Gleiss Lutz lawyers advised Pitango: Dr. Martin Viciano Gofferje (partner), Dr. Micha Pfarr (both lead, counsel), Dr. Christoph Meissner, Dr. Nora Schaffer (all Corporate/M&A), Dr. Enno Burk, Christoph Schoppe (both Healthcare/Regulatory), Dr. Rut Steinhauser (partner), Anke Siemer-Arcq (both Employment, all Berlin), Dr. Jacob von Andreae (partner), Aylin Hoffs, Vivien Etzkorn (all Public Business Law, all Düsseldorf), Simon Clemens Wegmann (Data Protection, Berlin), Dr. Eva Reudelhuber (partner), Pascal Urban (both Banking & Finance, both Munich), Dr. Stefan Mayer (partner), Dr. Leonhard Kornwachs (both Tax, both Frankfurt).
Gleiss Lutz regularly advises German and international companies and investors on investments in the healthcare and life sciences sector, most recently Curaleaf on its acquisition of a majority stake in Four 20 Pharma, the shareholders of PlasmidFactory GmbH & Co KG on the investment by ArchiMed and Klara on its acquisition by Modernizing Medicine.
Forward
